GlobeNewswire

Percona Delivers MyRocks Storage Engine for MySQL

Dela

First Experimental Release of MyRocks with Percona Server for MySQL Enables Greater Performance at Lower Cost for High-Volume, Write-Intensive Workloads

DUBLIN, Ireland, Sept. 26, 2017 (GLOBE NEWSWIRE) -- PERCONA LIVE OPEN SOURCE DATABASE CONFERENCE EUROPE Percona, the company that delivers enterprise-class MySQL®, MongoDB® and other open source database solutions and services, today announced an experimental full release of Percona Server for MySQL 5.7 that includes the MyRocks storage engine. The powerful combination of Percona Server for MySQL and MyRocks will enable database administrators to achieve more throughput for high-volume, write-intensive workloads. Optimized for modern hardware, the product requires less storage space and reduces maintenance costs, providing increased ROI for on-premises and cloud-based applications.

MyRocks, which integrates RocksDB as a MySQL storage engine, is optimized for modern hardware. When testing of the experimental combination of Percona Server and MyRocks is complete, the product will be ideal for today's high-volume, write-intensive applications such as data aggregation, IoT, transaction logging, system monitoring, payment processing and billing systems.

The MyRocks storage engine is based on the RocksDB key-value store, which is a log-structured merge-tree (LSM) that uses much less space and has a much smaller write volume (write amplification) compared to a B+ tree database, such as InnoDB. As a result, when used with fast storage, such as SSDs, MyRocks requires less storage space, provides more storage endurance, and ensures better IO capacity.

Percona Server for MySQL® is a free, fully compatible, enhanced, open source drop-in replacement for MySQL that provides superior performance, scalability and instrumentation. With more than 3,600,000 downloads, Percona Server for MySQL offers self-tuning algorithms and support for extremely high-performance hardware, delivering excellent performance and reliability. Percona Server for MySQL is trusted by thousands of enterprises to provide better performance and concurrency than other MySQL servers. Percona Server for MySQL also provides greater scalability and availability, enhanced backups and increased visibility.

Quotes

Peter Zaitsev,  Co-founder and CEO of Percona
"MyRocks has proven to be a superior storage engine for high-volume, write-intensive applications, and we are proud to be working with Facebook to include MyRocks in a package that delivers all the other advantages of Percona Server for MySQL, including greater performance, scalability, availability and visibility. The combined solution will enable our customers to do significantly more processing at a much lower cost, leading to improved ROI and a better end user experience."

Mark Callaghan ,  MTS, Facebook
"The efficiency improvements in MyRocks make it a great complement to Percona Server for MySQL. The MySQL community can now fully benefit from the storage engine, and we are thrilled to have worked with Percona to make this happen."

Company Information

Press Contact
Brigit Valencia
For Percona
(360) 597-4516
bdbvalencia@gmail.com

About Percona

With more than 3,000 customers worldwide, Percona is the only company that delivers enterprise-class solutions for both MySQL® and MongoDB® across traditional and cloud-based platforms. The company provides SoftwareSupportConsulting, and Managed Services to large, well-known global brands such as Cisco Systems, Time Warner Cable, Alcatel-Lucent, Rent the Runway and the BBC, as well as smaller enterprises looking to maximize application performance while streamlining database efficiencies. Well established as thought leaders, Percona experts author content for the Percona Database Performance Blog and the Percona Live Open Source Database Conferences draw attendees and expert technical speakers from around the world. For more information, visit www.percona.com.

Percona® is a registered trademark of Percona LLC. All other registered and unregistered trademarks in this document are the sole property of their respective owners.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Percona via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum